Cidara Therapeutics Stock Discussion

$Cidara Therapeutics (CDTX.US)$ On my top watchlist.
Cash available will sustain the operations for 24 months (exclude 105mil private placement). Upcoming catalyst September 2025.

$Cidara Therapeutics (CDTX.US)$ Cidara Therapeutics to Raise $105M Via Private Placement >CDTX

$Cidara Therapeutics (CDTX.US)$ 🥳🥳🥳

$Cidara Therapeutics (CDTX.US)$ on Watch

$Cidara Therapeutics (CDTX.US)$ creeping up

$Cidara Therapeutics (CDTX.US)$
Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenzau
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced the first sub...

$Cidara Therapeutics (CDTX.US)$ nice..

$Cidara Therapeutics (CDTX.US)$ Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
Dow Jones· 1 min ago

$Cidara Therapeutics (CDTX.US)$ Cidara Therapeutics Regains Compliance With Nasdaq's Requirements For Continued Listing

$Cidara Therapeutics (CDTX.US)$
NEWS
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
Cidara Therapeutics announced data presentations at ESCMID 2024 on CD388, highlighting Phase 1 and Phase 2a clinical data. The Phase 2a study showed CD388 was well-tolerated with significant antiviral effects in healthy volunteers challenged with influenza. The Phase 1 study demonstrated an extended half-life of 6-8 weeks, indicating potential f...